Search

everythinglearnresearchcommunity

for

Search:↓

Upadacitinib improved multiple immune-related conditions in one patient.

Guselkumab effectively treats skin reactions caused by adalimumab in certain conditions.

Certolizumab effectively treats psoriasis and psoriatic arthritis with fewer side effects than adalimumab.

Higher monocyte counts may predict poor response to adalimumab in hidradenitis suppurativa patients.

Upadacitinib significantly improved both rheumatoid arthritis and alopecia areata in a patient.

Liposomal adapalene improves delivery to hair follicles and reduces side effects for acne treatment.

Upadacitinib may effectively treat both alopecia universalis and Crohn's disease.

Upadacitinib effectively treats severe alopecia areata and is safe.

Upadacitinib effectively treated a patient with multiple inflammatory conditions.

Upadacitinib and oral minoxidil improved Crohn's disease and hair regrowth in a patient.

Upadacitinib significantly improved alopecia universalis and psoriatic arthritis in a patient.

A woman with rheumatoid arthritis lost all her hair during adalimumab treatment, and stopping the drug didn't help.

Upadacitinib helped regrow hair and maintain ulcerative colitis remission.

Microemulsions improve adapalene's skin absorption for better acne treatment.

Upadacitinib improved both Crohn's ileitis and alopecia universalis in a patient.

Upadacitinib improved Crohn's disease, atopic dermatitis, and alopecia areata in one patient.

Upadacitinib may help treat difficult cases of systemic lupus erythematosus.

Upadacitinib effectively treats psoriasiform eczema and some related conditions.

Upadacitinib improves life quality for Alopecia Areata patients without worsening skin issues.

Adalimumab helped control a child's severe eye disease when other treatments failed.

Upadacitinib effectively treats skin conditions like eczema and psoriasis and is becoming more widely used and affordable.

Polymeric micelle nanocarriers deliver adapalene more effectively to hair follicles than commercial products.

Upadacitinib is safe and effective for treating alopecia areata and atopic dermatitis in children.

Upadacitinib significantly improved a man's severe scalp condition when other treatments failed.

SIG-1451 could be a promising new treatment for atopic dermatitis.

Upadacitinib effectively treated severe atopic dermatitis, vitiligo, and alopecia areata in one patient.

Nemolizumab improved both severe atopic dermatitis and alopecia areata in one patient.

Abrocitinib is being evaluated for safety and effectiveness in treating moderate to severe atopic dermatitis.

IMTA can help regrow hair in severe alopecia areata when JAK inhibitors don't work well.